RediNews
ETFs Holding MCRB »    MCRB Historical Stock Prices »
MCRB News Video: Mon, Mar 25, 2019, 1:51 PM — Monday 3/25 Insider Buying Report: ARR, OTEL


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Seres Therapeutics is a microbiome therapeutics platform company developing a class of biological drugs, which it refers to as Ecobiotic® microbiome therapeutics. Using its microbiome therapeutics platform, Co. is developing its primary clinical product candidate, SER-109, which is designed to repair dysbiosis in the colonic microbiome in the setting of recurrent Clostridium difficile infection (CDI). Co. is developing SER-262, an ecology of spore forming bacteria to be used following antibiotic treatment for primary CDI to prevent an initial recurrence of CDI. Co. also has a clinical study for its inflammatory bowel disease drug candidate, SER-287. Self directed investors in Seres Therapeutics Inc will be interested in keeping up with all Seres Therapeutics Inc news they can find, both MCRB news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on MCRB. At RediNews, we simplify this task by presenting both MCRB news releases originating from Seres Therapeutics Inc itself, and MCRB news from a variety of media outlets. Visitors can browse this news online and through our MCRB RSS news feed.

MCRB News

MCRB News — Articles, Videos, & Press Releases

Commit To Purchase Seres Therapeutics At $5, Earn 19% Annualized Using Options
Thursday, March 21, 2019, 12:01 PM — Stock Options Channel
Notable Monday Option Activity: PTE, BGS, MCRB
Monday, March 11, 2019, 3:17 PM — Stock Options Channel
Sum Up The Parts: SPSM Could Be Worth $35
Friday, March 8, 2019, 7:41 AM — ETF Channel
Analysts Forecast 17% Upside For PBSM
Thursday, January 31, 2019, 7:43 AM — ETF Channel
Jim Simons Vs. The Shorts: Five Surprising Holdings
Tuesday, January 29, 2019, 10:31 AM — Dividend Channel
Short Sellers Drawn To These Five Jim Simons Holdings
Thursday, December 27, 2018, 11:19 AM — Dividend Channel
Analysts Anticipate IBB Will Reach $141
Tuesday, December 25, 2018, 8:46 AM — ETF Channel
Commit To Buy Seres Therapeutics At $5, Earn 12.3% Annualized Using Options
Thursday, December 20, 2018, 11:29 AM — Stock Options Channel
Seres Therapeutics is Now Oversold (MCRB)
Tuesday, December 18, 2018, 4:29 PM — Dividend Channel
Short Sellers Drawn To These Five Jim Simons Holdings
Wednesday, December 12, 2018, 10:45 AM — Dividend Channel
Seres Therapeutics (MCRB) Shares Cross Above 200 DMA
Thursday, November 8, 2018, 2:41 PM — Market News Video
Implied PBSM Analyst Target Price: $33
Thursday, September 27, 2018, 7:50 AM — ETF Channel
Commit To Buy Seres Therapeutics At $5, Earn 14% Annualized Using Options
Friday, September 21, 2018, 1:02 PM — Stock Options Channel
Commit To Purchase Seres Therapeutics At $7.50, Earn 26.4% Annualized Using Options
Thursday, June 21, 2018, 12:04 PM — Stock Options Channel
Sum Up The Pieces: VFQY Could Be Worth $92
Thursday, April 19, 2018, 9:15 AM — ETF Channel
Seres Therapeutics is Now Oversold (MCRB)
Tuesday, March 27, 2018, 4:35 PM — Dividend Channel
MCRB is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

AQXP News
EDG News
CFN News
DGX News
ISRG News
CVD News
TMO News
AMGN News
GILD News
ALXN News

Consider RediNews RSS feeds to complement your web page financial content. Whether below a detailed quote page, a stock history chart, or featured on your home page, RediNews has an RSS feed to meet your needs. Integrate news by specific stock symbol, or an entire market sector. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): .

MCRB News | www.RediNews.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.